Skip to main content
Industry News
Study shows improved magnesium levels among SGLT2 inhibitor users

Findings published in the Journal of Diabetes and its Complications found that 77.3% of 4,398 adults with type 2 diabetes had a serum magnesium level of at least 0.74 mmol/L after taking 10 mg of dapagliflozin daily for 24 weeks, compared with 29.5% of those in the placebo group. The analysis also showed that SGLT2 inhibitor treatment more effectively reduced blood pressure and heart rate measures than placebo.

Full Story: